Alvotech SA (NASDAQ:ALVO) Surpasses Q2 2025 Estimates with Strong Revenue and EPS Growth Alvotech SA (
NASDAQ:ALVO ) reported strong Q2 2025 earnings, beating revenue and EPS estimates with 41% growth. Shares surged 8.5% post-announcement.
Curious about the stocks that are showing activity after the closing bell on Wednesday? After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Why Is Alvotech Stock Trading Higher On Wednesday? Alvotech acquires Swiss packaging firm Ivers-Lee to boost biosimilar production capacity ahead of three 2025 launches.
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.
Why Is Teva Stock Trading Higher On Tuesday? Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.
Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden.
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.
